Analysts have been eager to weigh in on the Healthcare sector with new ratings on Grifols SA (GRFS) and Qiagen (QGEN).
Grifols SA (GRFS)
In a report issued on November 10, David Evans from Kepler Capital maintained a Hold rating on Grifols SA, with a price target of EUR28.30. The company’s shares closed last Wednesday at $18.83.
According to TipRanks.com, Evans is a 4-star analyst with an average return of 11.0% and a 75.4% success rate. Evans covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Crossject SA, and Pharnext SA.
Grifols SA has an analyst consensus of Moderate Buy, with a price target consensus of $31.11.
See today’s analyst top recommended stocks >>
Qiagen (QGEN)
Qiagen received a Buy rating and a EUR51.00 price target from Kepler Capital analyst Maja Pataki on November 10. The company’s shares closed last Wednesday at $46.51.
According to TipRanks.com, Pataki has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -11.6% and a 26.1% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Siemens Healthineers AG, Koninklijke Philips, and Tecan Group AG.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qiagen with a $57.72 average price target, representing a 25.4% upside. In a report issued on October 28, J.P. Morgan also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
